GB0402356D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0402356D0
GB0402356D0 GBGB0402356.0A GB0402356A GB0402356D0 GB 0402356 D0 GB0402356 D0 GB 0402356D0 GB 0402356 A GB0402356 A GB 0402356A GB 0402356 D0 GB0402356 D0 GB 0402356D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0402356.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0402356.0A priority Critical patent/GB0402356D0/en
Publication of GB0402356D0 publication Critical patent/GB0402356D0/en
Priority to EP05702083A priority patent/EP1711475A1/en
Priority to JP2006551904A priority patent/JP2007520537A/ja
Priority to PCT/GB2005/000341 priority patent/WO2005075440A1/en
Priority to US10/597,476 priority patent/US20090264452A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0402356.0A 2004-02-03 2004-02-03 Novel compounds Ceased GB0402356D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0402356.0A GB0402356D0 (en) 2004-02-03 2004-02-03 Novel compounds
EP05702083A EP1711475A1 (en) 2004-02-03 2005-02-01 2-(phenylamino)-pyrimidin-5-amides as cannabinoid 2 receptors modulators for the treatment of immune or inflammatory disorders.
JP2006551904A JP2007520537A (ja) 2004-02-03 2005-02-01 免疫病または炎症障害を治療するためのカンナビノイド2受容体の調節剤としての2−(フェニルアミノ)−ピリミジン−5−アミド
PCT/GB2005/000341 WO2005075440A1 (en) 2004-02-03 2005-02-01 2- (phenylamino) -pyrimidin-5-amides as cannabinoid 2 receptors modulators for the treatment of immune or inflammatory disorders
US10/597,476 US20090264452A1 (en) 2004-02-03 2005-02-01 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402356.0A GB0402356D0 (en) 2004-02-03 2004-02-03 Novel compounds

Publications (1)

Publication Number Publication Date
GB0402356D0 true GB0402356D0 (en) 2004-03-10

Family

ID=31985568

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0402356.0A Ceased GB0402356D0 (en) 2004-02-03 2004-02-03 Novel compounds

Country Status (5)

Country Link
US (1) US20090264452A1 (https=)
EP (1) EP1711475A1 (https=)
JP (1) JP2007520537A (https=)
GB (1) GB0402356D0 (https=)
WO (1) WO2005075440A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113109571A (zh) * 2021-03-19 2021-07-13 浙江工商大学 一种用于评估个体过敏程度的试剂盒

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007125049A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Use of cbx cannabinoid receptor modulators as potassium channel modulators
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
KR20120002581A (ko) 2009-03-30 2012-01-06 아스텔라스세이야쿠 가부시키가이샤 피리미딘 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
HUT63941A (en) * 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
CA2230894A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US20020183335A1 (en) * 2001-02-20 2002-12-05 Piyasena Hewawasam 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US20060247261A1 (en) * 2002-08-21 2006-11-02 Eatherton Andrew J Pyrimidine compounds
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
GB0222495D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113109571A (zh) * 2021-03-19 2021-07-13 浙江工商大学 一种用于评估个体过敏程度的试剂盒

Also Published As

Publication number Publication date
US20090264452A1 (en) 2009-10-22
EP1711475A1 (en) 2006-10-18
WO2005075440A1 (en) 2005-08-18
JP2007520537A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
GB0400812D0 (en) Novel compounds
GB0409744D0 (en) Novel compounds
EP1718638A4 (en) NEW COMPOUNDS
GB0402140D0 (en) Novel compounds
GB0405628D0 (en) Novel compounds
GB0402496D0 (en) Novel compounds
GB0402357D0 (en) Novel compounds
EP1805132A4 (en) NEW COMPOUNDS
GB0408083D0 (en) Novel compounds
EP1796793A4 (en) NEW CONNECTIONS
GB0402355D0 (en) Novel compounds
GB0402812D0 (en) Novel compounds
GB0402356D0 (en) Novel compounds
GB0402380D0 (en) Novel compounds
GB0404105D0 (en) Novel compounds
GB0404563D0 (en) Novel compounds
GB0402144D0 (en) Novel compounds
GB0406029D0 (en) Novel compounds
GB0406027D0 (en) Novel compounds
GB0406031D0 (en) Novel compounds
GB0404579D0 (en) Novel compounds
GB0406032D0 (en) Novel compounds
GB0404565D0 (en) Novel compounds
GB0404564D0 (en) Novel compounds
GB0406033D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)